# Poseidon’s Trident: “Divine” Intervention in Cervical Cancer Through Chemoradiation, Immunotherapy, and Antibody–Drug Conjugates

## TL;DR

This review explores how combining chemoradiation, immunotherapy, and antibody–drug conjugates can improve cervical cancer treatment outcomes.

## Contribution

The paper integrates cervical cancer biology with current treatment strategies to propose optimized multimodal approaches.

## Key findings

- Chemoradiation remains key for local control, while immunotherapy can enhance antitumor activity in specific biomarker contexts.
- Antibody–drug conjugates may promote immunogenic cell death and support combination therapies.
- Biomarker-informed strategies are crucial for managing resistance and toxicity in multimodal treatment.

## Abstract

Cervical cancer remains a major cause of illness and death worldwide, especially in settings with limited access to prevention, screening, and timely treatment. Standard treatment can cure many patients with localized disease, but some cancers return or spread due to therapeutic resistance or immune system evasion. This review takes a deeper dive into the biological mechanisms of cervical cancer development to examine the rationale behind different treatment strategies—from traditional, standard-of-care chemoradiation therapy to state-of-the-art immunotherapy and targeted drug delivery using antibody–drug conjugates. This review highlights how the interplay between core molecular biology and modern treatment approaches may help to optimize combination strategies, improve outcomes, and ultimately maximize patient care while informing future research directions.

Background/Objectives: Cervical cancer remains a leading cause of cancer morbidity and mortality worldwide. Although chemoradiation followed by brachytherapy is the curative-intent standard for locally advanced disease, outcomes remain heterogeneous and recurrence and distant metastasis persist. In parallel, immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) have expanded systemic options in recurrent or metastatic settings and created new opportunities for multimodality. This review aims to integrate treatment-relevant cervical cancer biology and biomarkers to clarify how chemoradiation, immunotherapy, and ADCs can be optimally selected, sequenced, and combined across disease states. Methods: We conducted a structured narrative, evidence-based literature synthesis focusing on cervical cancer management. The review encompassed: (i) the molecular and immune mechanisms underlying human papillomavirus (HPV)-driven carcinogenesis; (ii) contemporary diagnostic and staging approaches, including advanced imaging modalities and histopathological evaluation; and (iii) clinical and translational evidence supporting the optimization of chemoradiation, immune checkpoint inhibition, and antibody–drug conjugates, with emphasis on clinically validated or emerging biomarkers that are relevant to patient stratification and mechanistically rational combination or sequencing strategies. A systematic search of PubMed/MEDLINE, Embase, and major oncology conference proceedings was performed. Priority was given to peer-reviewed original research articles, high-impact clinical trials (Phase II–III), meta-analyses, and consensus guidelines published within the past 10 years to ensure contemporary relevance. Articles published prior to this period were generally excluded to maintain clinical currency; however, seminal studies that established foundational therapeutic standards, mechanistic paradigms, or landmark treatment milestones were intentionally retained due to their enduring influence on current practice. Exclusion criteria included non-peer-reviewed sources, case reports with limited generalizability, non-English publications, and studies lacking methodological rigor or clinical relevance to cervical cancer management. Preclinical studies were included selectively when directly informing therapeutic mechanisms, biomarker development, or translational rationale. This approach was designed to balance historical context with up-to-date clinical applicability, ensuring both scientific rigor and contemporary relevance. Results: Chemoradiation and brachytherapy remain essential for local control, while ICIs can restore antitumor T-cell activity in biomarker-enriched contexts. ADCs enable target-directed delivery of potent cytotoxins and may promote immunogenic cell death, supporting immunotherapy and radiation. However, key challenges include resistance mechanisms, toxicity management, and patient identification for the most beneficial combined multimodality. Conclusions: A biology- and biomarker-informed framework can guide more rational integration of multimodality therapy in cervical cancer. Future progress will depend on validated predictive biomarkers, optimized sequencing/combination strategies, and trials that balance efficacy with short- and long-term toxicity.